This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-02 and is reviewed periodically as new material appears.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Crosstalk with RNA editing === The type of RNA editing that is most prevalent in higher eukaryotes converts adenosine nucleotides into inosine in dsRNAs via the enzyme adenosine deaminase (ADAR). It was originally proposed in 2000 that the RNAi and A→I RNA editing pathways might compete for a common dsRNA substrate. Some pre-miRNAs do undergo A→I RNA editing and this mechanism may regulate the processing and expression of mature miRNAs. Furthermore, at least one mammalian ADAR can sequester siRNAs from RNAi pathway components. Further support for this model comes from studies on ADAR-null C. elegans strains indicating that A→I RNA editing may counteract RNAi silencing of endogenous genes and transgenes.
Projections to areas caudal to the hypothalamus go through the medial forebrain bundle, the mammillotegmental tract and the dorsal longitudinal fasciculus. Projections to areas rostral to the hypothalamus are carried by the mammillothalamic tract, the fornix and terminal stria. Projections to areas of the sympathetic motor system (lateral horn spinal segments T1–L2/L3) are carried by the hypothalamospinal tract and they activate the sympathetic motor pathway.
The driver, Nicolaas Fourie, and his two passengers promptly surrendered and were disarmed. After the media were allowed to photograph the badly injured prisoners, they were then executed at point-blank range by a Bophuthatswana policeman, Ontlametse Bernstein Menyatswe. These killings effectively spelt the end of white right-wing military opposition to democratic reforms. On 12 March 1994, Mangope was deposed as President of Bophuthatswana by the South African government and the Transitional Executive Council. South African Ambassador to Bophuthatswana, Prof. Tjaart van der Walt, was then appointed as the territory's new administrator.
In December 2025, the Food and Drug Administration announced that it would offer "agentic AI capabilities" to its staff for "meeting management, pre-market reviews, review validation, post-market surveillance, inspections and compliance and administrative functions." That same month, the United States Department of Defense launched GenAI.mil, an internal platform for American military personnel to use generative AI-based applications based on Google Gemini, including "intelligent agentic workflows". Defense Secretary Pete Hegseth listed applications such as "[conducting] deep research, [formatting] documents and even [analyzing] video or imagery at unprecedented speed." In December 2025, the United States Immigration and Customs Enforcement agency signed a contract with a company for its Enforcement and Removal Operations department to use AI agents for skip tracing.
In a complementary technique, peptide mass fingerprinting involves digestion of the native and modified protein with a protease such as trypsin. This will produce a set of peptides that can be analysed using a mass spectrometer. The peptide that changes in mass after reaction with the inhibitor will be the one that contains the site of modification.
Sources: en.wikipedia.org
By the 1801 Treaty of Lunéville, the last Este Duke was compensated with the Breisgau region of the former Further Austrian territories in southwestern Germany, and died in 1803. Following his death, the claims to the no longer existing ducal crown of Modena were inherited by his son-in-law, the Habsburg-Lorraine Archduke Ferdinand of Austria, an uncle of Emperor Francis II.
=== Dextran nanoparticle applications === Dextran nanoparticles have advantages such as increased drug-loading capacity, improved cellular uptake, reduce off-site toxicity, and increase local drug concentrations at the target tissue site. The current research indicates that dextran nanoparticles can potentially have applications in the delivery of anti-tumor therapeutics.
==== Privatization of waterways in the North, Recife Metro and COMPESA ==== In June 2025, the Lula government, despite strong popular opposition, supported the privatization of the Recife Metro and of the COMPESA (the Pernambuco sanitation company responsible for water supply in the state), measures announced by the governor of Pernambuco, Raquel Lyra. In both cases, the BNDES, under the leadership of Aloizio Mercadante, organized the studies to make the privatization process feasible and will also conduct the bidding procedures. In late May, the chief of staff, Rui Costa, had already confirmed that the Recife Metro would be privatized, continuing a process initiated in 2019 during the Jair Bolsonaro administration. The argument used by the government to justify the measure is that the metro system generates only financial losses. The decision prompted protests in Pernambuco, especially in Recife. In addition, in September 2025 the government included the waterway of the Madeira River and the waterways of the Tocantins and Tapajós rivers in the National Privatization Program (PND), a measure that also received criticism. During the 2022 presidential campaign and in government, Lula strongly criticized the privatizations carried out by the previous administration and even promised that the Recife Metro would not be privatized. The privatization measures were criticized especially by the more radical sectors of the Brazilian left, which also criticized the government's attempt to soften the term “privatization” by presenting them as “concessions”.
=== Mechanism of action === Aceclidine is a selective muscarinic acetylcholine receptor agonist used primarily in ophthalmology. Its mechanism of action involves binding preferentially to muscarinic receptors on the iris sphincter muscle, leading to pupillary constriction (miosis) with minimal stimulation of the ciliary muscle. Unlike non-selective miotic agents such as pilocarpine, aceclidine's selectivity results in a pronounced reduction in pupil size without significant induction of accommodation or myopic shift, thereby minimizing side effects like lens thickening or accommodative spasm. This targeted action is leveraged in the treatment of presbyopia, where the drug induces a “pinhole” effect: by creating a small, stable pupil, aceclidine increases the depth of focus and improves near vision while maintaining distance visual acuity. Its limited activity on the ciliary muscle distinguishes it from other cholinergic agonists and offers a favorable safety profile, with a reduced risk of retina or vitreous traction and fewer accommodative disturbances.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.